Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT02266030

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02266030
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02266030. Randomized; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2016-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM
Acronym
ESCAPE
Intervention (Drug)
Cilostazol
Intervention (Drug)
Aspirin
Lead sponsor
Seoul National University Bundang Hospital (class: other)

Record details

Record id
cardio:ct-nct02266030
Content hash
3da0977254bfaf7bdd2140c842db408544c13211b7b7d06eda4df654ff709be2